Bellerophon Therapeutics Inc (BLPH) Major Shareholder Associates Iv L. P. Venrock Buys 475,000 Shares
Bellerophon Therapeutics Inc (NASDAQ:BLPH) major shareholder Associates Iv L. P. Venrock bought 475,000 shares of the stock in a transaction dated Wednesday, September 12th. The shares were acquired at an average price of $1.18 per share, with a total value of $560,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
NASDAQ:BLPH opened at $1.22 on Friday. Bellerophon Therapeutics Inc has a one year low of $0.47 and a one year high of $3.30.
Bellerophon Therapeutics (NASDAQ:BLPH) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.10). equities analysts predict that Bellerophon Therapeutics Inc will post -0.4 EPS for the current fiscal year.
A hedge fund recently bought a new stake in Bellerophon Therapeutics stock. DRW Securities LLC purchased a new position in Bellerophon Therapeutics Inc (NASDAQ:BLPH) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 70,000 shares of the biotechnology company’s stock, valued at approximately $146,000. DRW Securities LLC owned approximately 0.12% of Bellerophon Therapeutics as of its most recent filing with the Securities & Exchange Commission. 58.49% of the stock is owned by hedge funds and other institutional investors.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.